

PRESS RELEASE

Ad hoc announcement pursuant to article 53 LR

LEPU Medical Technology(Beijing) Announces Results for the First Quarter of 2023

Beijing, China, April 25, 2023- LEPU Medical Technology(Beijing) Co.,Ltd.(the “Company”) today announced its performance for the first quarter of 2023:

- During the reporting period, the Company's operating income was RMB 2437.2024 million, RMB 111.9089 million lower than that of the same period of last year, with a decrease of 4.39%, mainly due to the high cardinal utility of detection reagent products related to COVID-19 in the same period of last year.
- During the reporting period, the Company achieved a net profit of RMB 618.3185 million, with an increase of 10.00% compared with the same period of the last year; Net profits attributable to shareholders of the Company was RMB 596.9242 million, with a increase of 9.45% compared with that in the last year; net profit attributable to shareholders of the Company after deducting non-recurring profit and loss was RMB 562.4298 million, with an increase of 2.78% compared with that of the last year; After the influences of share-based payment fee confirmed by Lepu Diagnostic Technology and Lepu Xintai Technology and the restricted stock plan issued at the end of the period of the Company are eliminated of RMB 60.6962 million and exchange loss of RMB 43.5413 million, the net profit attributable to shareholders of the Company after non-recurring gains and losses were deducted was RMB 652.8196, with a year-on-year increase of 15.61%.

Financial Results(unaudited)

	Three Months Ended March 31, 2023	Three Months Ended March 31, 2022	% Change
Operating revenue(RMB)	2,437,202,386.92	2,549,111,243.52	-4.39%
Net profit attributable to shareholders of the Company (RMB)	596,924,222.49	545,393,656.31	9.45%
Net profit attributable to shareholders of	562,429,846.30	547,208,342.77	2.78%

the Company after deducting non-recurring profit and loss (RMB)			
Net cash flows from operating activities (RMB)	-134,203,435.01	448,932,891.19	-129.89%
Basic earnings per share (RMB /share)	0.3205	0.3054	4.94%
Diluted earnings per share (RMB /share)	0.3177	0.3030	4.85%
Return on weighted average net assets	3.86%	4.68%	-0.82%

Full 2023 First Quarter Report

The Full 2023 First Quarter Report is available on our website at

<https://en.lepumedical.com/investors/>.

Contact information

Ms. Weina Jiang

Phone: +86 010 80120622

E-mail: zqb@lepumedical.com

About LEPU

LEPU Medical Technology(Beijing) Co.,Ltd was the total-solution provider in the PRC across the full life cycle of cardiovascular disease management, with products and services encompassing medical devices, pharmaceuticals, and medical care solutions Company is one of the earliest companies in the PRC to offer coronary interventional products and have consolidated our first-mover advantage through relentless innovation since our inception in 1999. Our key products, namely, coronary drug-eluting stent, coronary bioresorbable scaffold, coronary drug-coated balloon, congenital heart disease occluder and coronary cutting balloon. Our leading R&D expertise and capabilities have enabled us to develop and successfully commercialize a comprehensive portfolio of products. We focus our R&D efforts on unmet clinical

needs. We have developed and commercialized the first fully biodegradable occluder in the world and many first Chinese brand products, such as coronary stent, cardiac pacemaker, bioresorbable scaffold and coronary cutting balloon. In addition, we are the first PRC company to apply AI technology to ECG devices. Furthermore, benefiting from our diverse technology platforms, we have developed over 80 product candidates for cardiovascular devices and peripheral artery devices across coronary artery diseases, structural heart diseases, cardiac rhythm management, electrophysiology and other segments.

Disclaimers

This announcement contains forward-looking statements, estimates, opinions and projections with respect to anticipated future performance of the Company ("forward-looking statements"). These forward-looking statements can be identified by the use of forward looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "intends," "may," "will" or "should" or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current views, expectations and assumptions of the management of the Company and involve significant known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Forward-looking statements should not be read as guarantees of future performance or results and will not necessarily be accurate indications of whether or not such results will be achieved. Any forward-looking statements included herein only speak as at the date of this release.